Business Description
Suzhou Zelgen Biopharmaceuticals Co Ltd
ISIN : CNE100003RP1
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.39 | |||||
Equity-to-Asset | 0.44 | |||||
Debt-to-Equity | 0.71 | |||||
Debt-to-EBITDA | -5.55 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 5.35 | |||||
Beneish M-Score | -2.64 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 134 | |||||
3-Year EBITDA Growth Rate | 8.9 | |||||
3-Year EPS without NRI Growth Rate | 3.4 | |||||
3-Year FCF Growth Rate | 12.3 | |||||
3-Year Book Growth Rate | -2.9 | |||||
Future 3-5Y Total Revenue Growth Rate | 70.23 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 21.84 | |||||
9-Day RSI | 31.88 | |||||
14-Day RSI | 39.15 | |||||
6-1 Month Momentum % | 16.86 | |||||
12-1 Month Momentum % | 29.24 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.95 | |||||
Quick Ratio | 1.83 | |||||
Cash Ratio | 1.68 | |||||
Days Inventory | 1379.77 | |||||
Days Sales Outstanding | 84.68 | |||||
Days Payable | 1383.07 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.3 | |||||
Shareholder Yield % | -1.47 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 92.88 | |||||
Operating Margin % | -46.89 | |||||
Net Margin % | -35.7 | |||||
FCF Margin % | -4.52 | |||||
ROE % | -11.14 | |||||
ROA % | -5.85 | |||||
ROIC % | -17.54 | |||||
ROC (Joel Greenblatt) % | -52.65 | |||||
ROCE % | -9.2 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 143.5 | |||||
PS Ratio | 33.05 | |||||
PB Ratio | 12.39 | |||||
Price-to-Tangible-Book | 12.92 | |||||
Price-to-Operating-Cash-Flow | 258.39 | |||||
EV-to-EBIT | -91.05 | |||||
EV-to-EBITDA | -91.05 | |||||
EV-to-Revenue | 31.02 | |||||
EV-to-FCF | -686.2 | |||||
Price-to-Net-Current-Asset-Value | 17.88 | |||||
Price-to-Net-Cash | 29.89 | |||||
Earnings Yield (Greenblatt) % | -1.1 | |||||
FCF Yield % | -0.14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Suzhou Zelgen Biopharmaceuticals Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ¥) | 488.45 | ||
EPS (TTM) (Â¥) | -0.66 | ||
Beta | 1.39 | ||
Volatility % | 43.36 | ||
14-Day RSI | 39.15 | ||
14-Day ATR (Â¥) | 2.305276 | ||
20-Day SMA (Â¥) | 66.16 | ||
12-1 Month Momentum % | 29.24 | ||
52-Week Range (Â¥) | 33.2 - 79.99 | ||
Shares Outstanding (Mil) | 264.71 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Suzhou Zelgen Biopharmaceuticals Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Suzhou Zelgen Biopharmaceuticals Co Ltd Stock Events
Event | Date | Price(Â¥) | ||
---|---|---|---|---|
No Event Data |
Suzhou Zelgen Biopharmaceuticals Co Ltd Frequently Asked Questions
What is Suzhou Zelgen Biopharmaceuticals Co Ltd(SHSE:688266)'s stock price today?
When is next earnings date of Suzhou Zelgen Biopharmaceuticals Co Ltd(SHSE:688266)?
Does Suzhou Zelgen Biopharmaceuticals Co Ltd(SHSE:688266) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |